-
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review Pharmacoeconomics (IF 4.4) Pub Date : 2024-03-15
Abstract Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with up to 32% of patients with NSCLC harboring an epidermal growth factor receptor (EGFR) mutation. NSCLC harboring an EGFR mutation has a dedicated treatment pathway, with EGFR tyrosine kinase inhibitors and platinum-based chemotherapy often being the therapy of choice. Objective The aim of this study was
-
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries Pharmacoeconomics (IF 4.4) Pub Date : 2024-03-12 Laura Panattoni, Mairead Kearney, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal, Brett Hauber
-
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap Pharmacoeconomics (IF 4.4) Pub Date : 2024-03-05 Erik Landfeldt, Hera Sandhu
-
Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary Pharmacoeconomics (IF 4.4) Pub Date : 2024-02-28
Abstract Objectives This study aimed to develop population norms for three preference-accompanied measures [EQ-5D-5L, Patient-Reported Outcomes Measurement Information System (PROMIS)-preference scoring system (PROPr) and Short-Form Six-Dimension (SF-6D)] in Hungary. Methods In November 2020, an online cross-sectional survey was conducted among a representative sample of the Hungarian adult general
-
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review Pharmacoeconomics (IF 4.4) Pub Date : 2024-02-13 Christine Mpundu-Kaambwa, Norma B. Bulamu, Lauren Lines, Gang Chen, David G. T. Whitehurst, Kim Dalziel, Nancy Devlin, Julie Ratcliffe
-
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review Pharmacoeconomics (IF 4.4) Pub Date : 2024-02-10 Billingsley Kaambwa, Taylor-Jade Woods, Andrea Natsky, Norma Bulamu, Christine Mpundu-Kaambwa, Kelly A. Loffler, Alexander Sweetman, Peter G. Catcheside, Amy C. Reynolds, Robert Adams, Danny J. Eckert
-
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression Pharmacoeconomics (IF 4.4) Pub Date : 2024-02-08 Rachel O’Loughlin, Renee Jones, Gang Chen, Brendan Mulhern, Harriet Hiscock, Nancy Devlin, Kim Dalziel
Objective The aim of this study was to examine the validity, reliability and responsiveness of common generic paediatric health-related quality of life (HRQoL) instruments in children and adolescents with mental health challenges. Methods Participants were a subset of the Australian Paediatric Multi-Instrument Comparison (P-MIC) study and comprised 1013 children aged 4–18 years with attention-deficit/hyperactivity
-
Incorporating Real Option Value in Valuing Innovation: A Way Forward Pharmacoeconomics (IF 4.4) Pub Date : 2024-02-04 Meng Li, Louis P. Garrison
-
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA Pharmacoeconomics (IF 4.4) Pub Date : 2024-02-01
Abstract Objective This study aimed to assess the budget impact of introducing fixed-duration mosunetuzumab as a treatment option for adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies and to estimate the total cumulative costs per patient in the USA. Methods A 3-year budget impact model was developed for a hypothetical 1-million-member cohort
-
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-27 Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Gang Chen, Kim Dalziel, Nancy Devlin, Julie Ratcliffe
-
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2–4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL) Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-27
Abstract Objective This study examines the psychometric properties of the Child Health Utility 9D (CHU9D) proxy version administered to parents/caregivers of 2–4-year-old Australian children compared with Pediatric Quality of Life Inventory™ version 4.0 (PedsQL). Methods Data collected in 2021/2022 from parents/caregivers of 2–4-year-olds from the Australian pediatric multi-instrument comparison study
-
The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-24
Abstract Background and Aim The prevalence of type 2 diabetes (T2D) is rapidly increasing in Sub-Saharan Africa (SSA). T2D increases the risk of premature death and reduces quality of life and work productivity. This population life table modelling analysis evaluated the impact of T2D in terms of productivity-adjusted life years (PALYs) on the South African working-age population. Research Design and
-
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-24 Anita J. Brogan, Ashley E. Davis, Claire E. Mellott, Jeremy Fraysse, Aimee A. Metzner, Alan K. Oglesby
-
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-24 Clara Marquina, Jedidiah I Morton, Melanie Lloyd, Dina Abushanab, Yeji Baek, Tamrat Abebe, Adam Livori, Padam Dahal, Gerald F. Watts, Zanfina Ademi
-
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-18
Abstract Introduction Few preference-weighted instruments are available to measure health-related quality of life in young children (2–4 years of age). The EQ-5D-Y-3L and EQ-5D-Y-5L were recently modified for this purpose. Objective The aim of this study was to test the psychometric properties of these adapted versions for use with parent proxies of children aged 2–4 years and to compare their performance
-
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-18
Abstract Background The EuroQol Health and Wellbeing Short Version (EQ-HWB-S) instrument has been developed to measure the health and wellbeing of care-recipients and their caregivers for use in economic evaluation.The EQ-HWB-S has nine items, and pilot UK preference weights have now been developed. Objective We aimed to investigate the validity of the instrument in parents of children with and without
-
The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-13 Cate Bailey, Martin Howell, Rakhee Raghunandan, Kim Dalziel, Kirsten Howard, Brendan Mulhern, Stavros Petrou, Donna Rowen, Amber Salisbury, Rosalie Viney, Emily Lancsar, Nancy Devlin
-
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-09 Zakile A. Mfumbilwa, Martijn J. H. G. Simons, Bram Ramaekers, Valesca P. Retèl, Joanne M. Mankor, Harry J. M. Groen, Joachim G. J. V. Aerts, Manuela Joore, Janneke A. Wilschut, Veerle M. H. Coupé
-
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia Pharmacoeconomics (IF 4.4) Pub Date : 2024-01-06 Dong-Won Kang, Li Wang, Nicholas J. Short, Alessandra Ferrajoli, Yucai Wang, Shouhao Zhou, Chan Shen
-
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework Pharmacoeconomics (IF 4.4) Pub Date : 2023-12-29 Natalia Kunst, Emily A. Burger, Veerle M. H. Coupé, Karen M. Kuntz, Eline Aas
-
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada Pharmacoeconomics (IF 4.4) Pub Date : 2023-12-27 Diedron Lewis, William W. L. Wong, Joseph Lipscomb, Susan Horton
-
Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review Pharmacoeconomics (IF 4.4) Pub Date : 2023-12-27 Ana Helena Perea-Bello, Marta Trapero-Bertran, Christian Dürsteler
-
A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments Pharmacoeconomics (IF 4.4) Pub Date : 2023-12-12 T. Joseph Mattingly
-
A Framework for the Fair Pricing of Medicines Pharmacoeconomics (IF 4.4) Pub Date : 2023-12-08 Mike Paulden
-
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force Pharmacoeconomics (IF 4.4) Pub Date : 2023-12-02 Edward Henry, Hareth Al-Janabi, Werner Brouwer, John Cullinan, Lidia Engel, Susan Griffin, Claire Hulme, Pritaporn Kingkaew, Andrew Lloyd, Nalin Payakachat, Becky Pennington, Luz María Peña-Longobardo, Lisa A. Prosser, Koonal Shah, Wendy J. Ungar, Thomas Wilkinson, Eve Wittenberg
-
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-24 Jason Gordon, Maria Gheorghe, Cale Harrison, Ryan Miller, James Dennis, Lotte Steuten, Simon Goldenberg, Sumanth Gandra, Amer Al-Taie
-
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-21 Antal Zemplenyi, Jim Leonard, Michael J. DiStefano, Kelly E. Anderson, Garth C. Wright, Nicholas D. Mendola, Kavita Nair, R. Brett McQueen
-
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-22 Daniel Gladwell, Oriana Ciani, Adam Parnaby, Stephen Palmer
-
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective. Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-20 Giovany Orozco-Leal,Eugenie Evelynne Johnson,Sedighe Hosseinijebeli,Tomos Robinson,Tara Homer,Claire H Eastaugh,Catherine Richmond,Louise Tanner,Nick Meader,Ryan Kenny,Sheila A Wallace,Stephen Rice
-
Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-16 Lucinda J. Teoh, Salomey Kellett, Dipesh E. Patel, Mario Cortina-Borja, Ameenat Lola Solebo, Jugnoo S. Rahi
-
Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-13 Renee Jones, Rachel O’Loughlin, Xiuqin Xiong, Mina Bahrampour, Nancy Devlin, Harriet Hiscock, Gang Chen, Brendan Mulhern, Kim Dalziel
Objective The aim of this study was to compare the psychometric performance of common generic paediatric health-related quality-of-life instrument descriptive systems (PedsQL generic core 4.0, EQ-5D-Y-3L, EQ-5D-Y-5L, Child Health Utility 9D [CHU9D], Assessment of Quality of Life 6D [AQoL-6D], and Health Utilities Index Mark 3 [HUI3]) by child age, report type, and health status. Methods Data for children
-
Systematic Review of the Relative Social Value of Child and Adult Health Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-09 Tessa Peasgood, Martin Howell, Rakhee Raghunandan, Amber Salisbury, Marcus Sellars, Gang Chen, Joanna Coast, Jonathan C. Craig, Nancy J. Devlin, Kirsten Howard, Emily Lancsar, Stavros Petrou, Julie Ratcliffe, Rosalie Viney, Germaine Wong, Richard Norman, Cam Donaldson
-
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-09 Ramesh Lamsal, E. Ann Yeh, Eleanor Pullenayegum, Wendy J. Ungar
-
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-10 Junwen Zhou, Claire Williams, Mi Jun Keng, Runguo Wu, Borislava Mihaylova
-
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-07 Christopher W. Yee, Michael J. Harvey, Yiqiao Xin, Noam Y. Kirson
-
Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-01 Javier Mar, Oliver Ibarrondo, Carlo Delfin S. Estadilla, Nico Stollenwerk, Fernando Antoñanzas, Rubén Blasco-Aguado, Igor Larrañaga, Joseba Bidaurrazaga, Maíra Aguiar
-
The Carer QALY Trap and Altruism in Economic Evaluations. Pharmacoeconomics (IF 4.4) Pub Date : 2023-11-02 J Mick Tilford,Aygul Tarlan
-
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments Pharmacoeconomics (IF 4.4) Pub Date : 2023-10-27 Alex J. Turner, Cormac Sammon, Nick Latimer, Blythe Adamson, Brennan Beal, Vivek Subbiah, Keith R. Abrams, Joshua Ray
-
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition Pharmacoeconomics (IF 4.4) Pub Date : 2023-10-19 Daniel Tobias Michaeli, Thomas Michaeli
-
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective. Pharmacoeconomics (IF 4.4) Pub Date : 2023-10-05 Diarmuid Coughlan,Oluwatomi Arisa,Katie Thomson,Ge Yu,Fiona Pearson,Ashleigh Kernohan,Sonia Garcia Gonzalez-Moral,Sheila Wallace,Stephen Rice
-
Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis Pharmacoeconomics (IF 4.4) Pub Date : 2023-09-26 Melissa Lannon, Taylor Duda, Alexander Mastrolonardo, Ellissa Huang, Amanda Martyniuk, Forough Farrokhyar, Feng Xie, Mohit Bhandari, Suneil K. Kalia, Sunjay Sharma
-
A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus Pharmacoeconomics (IF 4.4) Pub Date : 2023-09-22 Marina Antoniou, Céu Mateus, Bruce Hollingsworth, Andrew Titman
-
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer Pharmacoeconomics (IF 4.4) Pub Date : 2023-09-14 Anthony J. Hatswell, Mohammad A. Chaudhary, Giles Monnickendam, Alejandro Moreno-Koehler, Katie Frampton, James W. Shaw, John R. Penrod, Rachael Lawrance
-
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap Pharmacoeconomics (IF 4.4) Pub Date : 2023-09-02 David J. Mott, Hannah Schirrmacher, Hareth Al-Janabi, Sophie Guest, Becky Pennington, Nicolas Scheuer, Koonal K. Shah, Chris Skedgel
The provision of informal (unpaid) care can impose significant ‘spillover effects’ on carers, and accounting for these effects is consistent with the efficiency and equity objectives of health technology assessment (HTA). Inclusion of these effects in health economic models, particularly carer health-related quality of life (QOL), can have a substantial impact on net quality-adjusted life year (QALY)
-
Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-22 Jedidiah I. Morton, Clara Marquina, Melanie Lloyd, Gerald F. Watts, Sophia Zoungas, Danny Liew, Zanfina Ademi
-
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-21 Daniel Hill-McManus
-
Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-19 Aneeka Hafeez, Lauren E. Cipriano, Richard B. Kim, Gregory S. Zaric, Ute I. Schwarz, Sisira Sarma
-
Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-17 Marieke Krol, Nikkie Hosseinnia, Werner Brouwer, Leona Hakkaart van Roijen
-
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-18 Deborah A. Marshall, Brittany Gerber, Diane L. Lorenzetti, Karen V. MacDonald, Riley Jewel Bohach, Gillian R. Currie
-
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-16 Jason Gordon, Maria Gheorghe, Simon Goldenberg, Ryan Miller, James Dennis, Amer Al-Taie
-
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-12 Michaela Carla Barbier, Alicia Fengler, Esther Pardo, Arjun Bhadhuri, Niklaus Meier, Oliver Gautschi
-
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs. Pharmacoeconomics (IF 4.4) Pub Date : 2023-08-02 Werner Brouwer,Pieter van Baal
-
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-28 Peter Gal, Gyorgyi Feldmajer, Margarida Augusto, Ray Gani, Emma Hook, Ash Bullement, Zoe Philips, Inger Smith
-
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-25 Kumar Mukherjee, Necdet B. Gunsoy, Rita M. Kristy, Joseph C. Cappelleri, Jessica Roydhouse, Judith J. Stephenson, David J. Vanness, Sujith Ramachandran, Nneka C. Onwudiwe, Sri Ram Pentakota, Helene Karcher, Gian Luca Di Tanna
-
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-25 Boshen Jiao
-
Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-18 David Teigen, Robert O. Opoka, Phillip Kasirye, Catherine Nabaggala, Heather A. Hume, Bjørn Blomberg, Chandy C. John, Russell E. Ware, Bjarne Robberstad
-
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-18 Xuejing Jin, Wanxian Liang, Lining Zhang, Shihuan Cao, Lujia Yang, Feng Xie
-
Conducting Trial-Based Economic Evaluations Using R: A Tutorial Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-17 Ângela Jornada Ben, Johanna M. van Dongen, Mohamed El Alili, Jonas L. Esser, Hana Marie Broulíková, Judith E. Bosmans
-
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-17 Jonathan D. Campbell, Melanie D. Whittington, Steven D. Pearson
-
Using Age-Specific Values for Pediatric HRQoL in a Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How? Pharmacoeconomics (IF 4.4) Pub Date : 2023-07-13 Nancy J. Devlin, Tianxin Pan, Mark Sculpher, Mark Jit, Elly Stolk, Donna Rowen, Barend van Hout, Richard Norman